Work

Novel composite nano-frameworks for prostate cancer therapy via synergistic targeting of ribonucleotide reductase

Year: 2025

Type: article

Abstract: Prostate cancer, a common malignancy in men, poses significant clinical challenges, especially as it progresses to castration-resistant prostate cancer (CRPC). Conventional therapies become less effective due to acquired drug resistance, and even enzalutamide (ENZR), a cornerstone treatment for CRPC, eventually faces resistance. Understanding the clinical significance of ENZR resistance is crucial for improving prostate cancer treatment. To address this issue, we developed an innovative nanosystem: Deferasirox (DEF)-loaded self-etched platinum-cobalt nanodendrites encapsulated within a nanoframe (Pt/Co-ND@DEF). This system combines chemodynamic therapy (CDT) with DEF delivery. Pt/Co-ND@DEF demonstrates potent peroxidase-like activity, catalyzing hydrogen peroxide (H2O2) decomposition and glutathione (GSH) depletion to generate reactive oxygen species (ROS). Additionally, DEF release reduces tumor iron ion (Fe3+) content, disrupting ribonucleotide reductase activity essential for DNA synthesis and arresting the cell cycle. This dual-action mechanism enhances ROS-induced cytotoxicity and boosts ENZR’s efficacy against CRPC, offering a promising multi-target strategy. Our study represents a significant step forward in overcoming ENZR resistance and enhancing prostate cancer treatment, providing new therapeutic avenues for advanced cases.

Source: Arabian Journal of Chemistry

DOI: 10.25259/ajc_73_2025

Authors: Mingwei Xu, Jun Chen, Chengran Huang, Cheng Liu

Institutions: Hubei University of Arts and Science, Xiangyang Central Hospital

Language: English

Topic: Nanoplatforms for cancer theranostics

Subfield: Biomedical Engineering

Field: Engineering

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $1,490